Changes After Suprachoroidal Injection.

Changes Noted After Suprachoroidal Triamcinolone Acetonide Injection.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05288192

Enrollment

Registered

2022-03-21

Start date

2022-02-15

Completion date

2022-09-01

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Intraocular Pressure, Macular Edema, Retina; Change

Brief summary

Changes after suprachoroidal injection are analyzed for statistical analysis.

Detailed description

Changes after suprachoroidal injection of triamcinolone acetonide are noted in various retinal diseases treated by this technique to address its effects over six months of follow-up.

Interventions

DRUGSuprachoroidal triamcinolone acetonide (SCTA) injection

Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients prepared to suprachoroidal injection for various retinal diseases will be enrolled in the study. * Bilateral retinal diseases that required interventions as diabetic macular edema, exudative retinal detachment, and serous chorioretinopathies.

Exclusion criteria

* Other retinal diseases that are not expected to improve after steroid injections as central retinal artery occlusion and age-related macular degenerations. * Choroidal neovascularization that require anti-vascular endothelial growth factors. * Patients refused to have steroid injections even after discussing the nature of their disease with them and the procedure to be done.

Design outcomes

Primary

Measure	Time frame	Description
Changes in visual acuity	Monthly after injection till six months of follow up	Changes in best corrected visual acuity after injection
Changes in central foveal thickness	Monthly after injection till six months of follow up	Changes in central macular thickness after injection

Secondary

Measure	Time frame	Description
Changes in intraocular pressure	Monthly after injection till six months of follow up	Changes in intraocular pressure after injection
Changes in lens	Monthly after injection till six months of follow up	Cataract progression after injection

Countries

Egypt

Contacts

Primary ContactAhmed Abdelshafy

ahmad4lg@gmail.com01222328766

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026